Annals of the New York Academy of Sciences · 2000 · 29 citations · 9 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyColorectal CancerCombination ImmunotherapyTumor AntigensTumor-associated AntigensChimeric Monoclonal AntibodiesMonoclonal Antibodies In CancerMonoclonal Antibodies In OncologyOncofetal AntigensT Cell Response InductionTherapeutic Cancer ImmunizationTumor Antigen-based ImmunotherapyTumor-associated Antigen Targeting
GA733/EpCAM is an oncofetal antigen abundantly expressed in colorectal carcinoma. This antigen can spontaneously induce a humoral and cellular antitumor immunity and may therefore be a suitable target structure for immunotherapy. Patients with advanced colorectal carcinoma have been treated with monoclonal antibodies (MAb17-1A) against this structure. The data indicate that the chimeric variant was not superior to the original mouse MAb. Addition of cytokines and chemotherapeutics may improve the therapeutic effect of the MAb. A particularly interesting regimen is a combination of MAb17-1A/GM-CSF/alpha-IFN/5-Fu. The GA733 protein antigen can also be used as a vaccine. Patients with colorectal carcinoma stages B and C were vaccinated with this protein antigen in combination with GM-CSF as an adjuvant cytokine. A strong type I T cell response was induced that seemed to be MHC class I as well as class II restricted. No systemic side effects were noted.
9
A. Samanci, Qing Yi, Jan Fagerberg et al. · Cancer Immunology Immunotherapy · 1998 · 111 citations · Full text